MetaCap

Lifevantage (LFVN) vs Xilio Therapeutics (XLO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xilio Therapeutics (XLO) has outperformed Lifevantage (LFVN) over the past year, losing 28.3% versus a loss of 35.5%. Over five years, LFVN leads with a -38.5% price change compared with -97.3% for XLO. Xilio Therapeutics is the larger company by market cap ($53.4 million vs $52.6 million), about 1.0 times the size.

On valuation, Xilio Therapeutics trades at a lower trailing P/E (11.6x vs 19.8x for Lifevantage). Lifevantage pays a dividend yielding 4.58%, while Xilio Therapeutics does not currently pay one. Lifevantage converts more of its revenue into profit, with a net margin of 2.8% versus -80.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LFVN-35.46%XLO-28.29%
+72%+14%-43%
Nov 21, 20251 yearNov 20, 2026
LFVN-43.84%XLO-97.63%
+260%+72%-115%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LFVN versus XLO key metrics
MetricLFVNXLO
Share price$4.15$7.56
Market cap$52.63M$53.40M
1-day change-15.13%-1.11%
YTD return-32.63%-15.63%
1-year return-35.46%-28.29%
5-year return-38.52%-97.29%
P/E ratio (TTM)19.7611.63
Forward P/E27.67—
EPS (TTM)$0.21$0.65
Dividend yield4.58%0.00%
Annual dividend$0.19$0.00
Revenue (latest FY)$182.59M$43.77M
Revenue growth (YoY)-20.10%+589.88%
Net income (latest FY)$5.07M$-35.04M
Gross margin77.56%—
Operating margin3.34%-95.92%
Net margin2.78%-80.05%
52-week high$11.71$10.71
52-week low$3.90$6.47
Distance from 52-week high-64.56%-29.41%
Analyst consensusnonenone
Avg. price target upside+80.72%+164.55%
Average volume45.72K11.54K
Shares outstanding12.68M7.06M
Employees20976
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Lifevantage trades at a higher earnings multiple (19.8x vs 11.6x trailing P/E).
  • Lifevantage offers a meaningfully higher dividend yield (4.58% vs 0.00%).
  • Lifevantage is more profitable, keeping 2.8 cents of every revenue dollar as net income versus -80.1 cents for Xilio Therapeutics.
  • Xilio Therapeutics grew revenue faster in its latest fiscal year (+589.88% vs -20.10%).

About Lifevantage

LFVN stock →

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; P84 System, a product activator consisting of PhytoPower 1 and PhytoPower 2 that contains probiotics, prebiotics, postbiotics, digestive enzymes, and superfood blends designed to support gut health; MindBody GLP-1 System, a dietary supplement that combines two products, MB Core and MB Enhance, which are designed to support weight management and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.

Health Care · Biotechnology: Pharmaceutical Preparations · 209 employees

About Xilio Therapeutics

XLO stock →

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

LFVN vs XLO FAQ

Which is bigger, Lifevantage or Xilio Therapeutics?

Xilio Therapeutics (XLO) is larger, with a market capitalization of $53.40M compared with $52.63M for Lifevantage (LFVN).

Which stock has performed better over the past year, LFVN or XLO?

XLO returned -28.29% over the past 12 months, compared with -35.46% for LFVN (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, LFVN or XLO?

XLO has the lower trailing P/E at 11.6, versus 19.8 for LFVN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Lifevantage or Xilio Therapeutics?

Lifevantage pays a dividend yielding 4.58%, while Xilio Therapeutics does not currently pay a regular dividend.

Are Lifevantage and Xilio Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons